These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2272037)

  • 21. Physiological and pharmacological effects of estrogens in breast cancer.
    Leclercq G; Heuson JC
    Biochim Biophys Acta; 1979 Dec; 560(4):427-55. PubMed ID: 391285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
    von Angerer E; Birnböck H; Knebel N
    Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells.
    Wakeling AE; Valcaccia B; Newboult E; Green LR
    J Steroid Biochem; 1984 Jan; 20(1):111-20. PubMed ID: 6538611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxy or counterpart function with the estrogen receptor.
    Borgna JL; Scali J
    Eur J Biochem; 1991 Aug; 199(3):575-85. PubMed ID: 1868844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroid hormone receptors in mammary carcinoma: the effect of tamoxifen.
    Koenders AJ; Beex LV; Geurts-Moespot J; Benraad TJ
    Eur J Cancer (1965); 1980; Suppl 1():63-6. PubMed ID: 7318871
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
    Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
    Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular conformation, receptor binding, and hormone action of natural and synthetic estrogens and antiestrogens.
    Duax WL; Griffin JF; Weeks CM; Korach KS
    Environ Health Perspect; 1985 Sep; 61():111-21. PubMed ID: 3905370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolactin and estrogen receptors in breast cancer.
    McGuire WL; Chamness GC; Horwitz KB; Zava DT
    Pathobiol Annu; 1977; 7():191-211. PubMed ID: 201904
    [No Abstract]   [Full Text] [Related]  

  • 29. 2-Phenylbenzo[b]furans: relationship between structure, estrogen receptor affinity and cytostatic activity against mammary tumor cells.
    Erber S; Ringshandl R; von Angerer E
    Anticancer Drug Des; 1991 Nov; 6(5):417-26. PubMed ID: 1764164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,1,2,2-tetraalkyl-1,2 -diphenylethanes.
    Hartmann RW; Kranzfelder G; von Angerer E; Schönenberger H
    J Med Chem; 1980 Aug; 23(8):841-8. PubMed ID: 7401112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A docking modelling rationally predicts strong binding of bisphenol A to estrogen-related receptor gamma.
    Nose T; Shimohigashi Y
    Protein Pept Lett; 2008; 15(3):290-6. PubMed ID: 18336360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a 2-D geometric descriptor associated with non-genotoxic carcinogens and some estrogens and antiestrogens.
    Rosenkranz HS; Cunningham A; Klopman G
    Mutagenesis; 1996 Jan; 11(1):95-100. PubMed ID: 8671723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
    Nichols M; Rientjes JM; Logie C; Stewart AF
    Mol Endocrinol; 1997 Jun; 11(7):950-61. PubMed ID: 9178754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low binding ability of the estrogen receptor from mammary tumors to heparin-sepharose.
    Michel O; Leclercq G; Toma S
    Anticancer Res; 1981; 1(6):403-8. PubMed ID: 7344615
    [No Abstract]   [Full Text] [Related]  

  • 35. Development of QSAR models to predict estrogenic, carcinogenic, and cancer protective effects of phytoestrogens.
    Singh AK
    Cancer Invest; 2001; 19(2):201-16. PubMed ID: 11296624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
    Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
    Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production and actions of estrogens.
    Gruber CJ; Tschugguel W; Schneeberger C; Huber JC
    N Engl J Med; 2002 Jan; 346(5):340-52. PubMed ID: 11821512
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative affinity of steroidal and non-steroidal antioestrogens, cholesterol derivatives and compounds with a dialkylamino side chain for the rat liver antioestrogen binding site.
    van den Koedijk CD; Vis van Heemst C; Elsendoorn GM; Thijssen JH; Blankenstein MA
    Biochem Pharmacol; 1992 Jun; 43(12):2511-8. PubMed ID: 1632810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ring-substituted 1,1,2,2-tetraalkylated 1,2-bis(hydroxyphenyl)ethanes. 4. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted 1,1,2,2-tetramethyl-1,2-bis(hydroxyphenyl)ethanes.
    Hartmann RW; Schwarz W; Heindl A; Schönenberger H
    J Med Chem; 1985 Sep; 28(9):1295-301. PubMed ID: 2993619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of action of antiestrogens and androgens on the estrogen receptor.
    Rochefort H; Capony F; Garcia M
    J Steroid Biochem; 1979; 11(5-6):1635-8. PubMed ID: 574911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.